This is a working overview of Heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-21 and is reviewed periodically as new material appears.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
== Genetics == The McLeod phenotype is a recessive mutation of the Kell blood group system. The McLeod gene encodes the XK protein, which is located on the X chromosome, and has the structural characteristics of a membrane transport protein but an unknown function. Absence of the XK protein is an X-linked disease. Mutational variants result in McLeod syndrome either with or without neuroacanthocytosis: the gene on the X chromosome for McLeod syndrome is physically close to the gene for chronic granulomatous disease. As a result, an individual with one relatively small deletion may have both diseases. The phenotype may be present without the syndrome presenting.
Hardness and richness of colour are two of the major factors in determining the value of turquoise; while colour is a matter of individual taste, generally speaking, the most desirable is a strong sky to robin egg blue (in reference to the eggs of the American robin). Whatever the colour, for many applications, turquoise should not be soft or chalky; even if treated, such lesser material (to which most turquoise belongs) is liable to fade or discolour over time and will not hold up to normal use in jewellery. The mother rock or matrix in which turquoise is found can often be seen as splotches or a network of brown or black veins running through the stone in a netted pattern; this veining may add value to the stone if the result is complementary, but such a result is uncommon. Such material is sometimes described as "spiderweb matrix"; it is most valued in the Southwest United States and Far East, but is not highly appreciated in the Near East where unblemished and vein-free material is ideal (regardless of how complementary the veining may be). Uniformity of colour is desired, and in finished pieces the quality of workmanship is also a factor; this includes the quality of the polish and the symmetry of the stone. Calibrated stones—that is, stones adhering to standard jewellery setting measurements—may also be more sought after. Like coral and other opaque gems, turquoise is commonly sold at a price according to its physical size in millimetres rather than weight. Turquoise is treated in many different ways, some more permanent and radical than others.
== Chemical designation == This compound belongs to a class of experimental compounds known as N-acyl-alpha-amino acids and their derivatives. These are compounds containing an alpha-amino acid (or its derivative) with an acyl group on the terminal nitrogen atom.
Sources: en.wikipedia.org
== The yachts == Early races had a very wide range of boat types, but concerns after the 1989–1990 race led to the development of the Whitbread 60 single design. This was a reaction to increasing costs of the biggest, "maxi", boats, and their advantage over the rest of the field – Steinlager 2 won every leg in the maxi division and was the winner overall, with many of the smaller boats finishing legs more than ten days after the winner. The Whitbread 60 design was used for all smaller boats in the 1993–1994 race, and for all in the 1997–1998 race. The race continued to be restricted to a single class for the next seven races – but moved to the Volvo Open 70, then the Volvo Ocean 65. Two classes of boats were used for the 2023 edition of the race: the Volvo Ocean 65 and the IMOCA 60.
=== Wax printing === Wax printing uses a simple printer to pattern wax on paper in a desired design. The wax is then melted with a hotplate to create channels. This technique is fast and low cost, but has relatively low resolution due to the isotropy of the melted wax.
== Research, teaching and training == As of 2025, the Department of Biochemistry, Cell and Systems Biology is composed of 46 tenured and tenure-track research-focused teaching academics, studying the Departmental research themes of cell biology, systems and computational biology, cell signaling, multiomics, photosynthesis and plants and mechanistic structural biology. The department is home to a broad selection of Early Career Researchers and senior Professorial staff including Sonia Rocha, a specialist in Hypoxia-inducible factor, Dan Rigden, noted for his work with CASP Douglas Kell, a leader in systems and synthetic biology, Claire Eyers, a proteomics and biological mass spectrometry expert, Luning Liu, Ben Goult, J Bernadette Moore, Richard Scheltema, Sylvie Urbe and Roy Goodacre, editor of the peer-reviewed journal Metabolomics (journal). The department possesses dedicated research, mentoring and technical professional support staff, all of whom were recognised through the award of a Gold Athena Swan Award in 2025, one of only a handful of Institutes in the UK to achieve this distinction,. Grant-funded research from across the UKRI, Wellcome, industrial and charity portfolios is performed in state-of-the-art facilities where biochemical approaches sit alongside cutting-edge multiomics technology to study the chemistry of life.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.